Swedish biotech raises €30M Series A to develop off-the-shelf gene therapy for solid tumors
As it advances its in vivo cell reprogramming platform, Asgard Therapeutics has raised €30 million ($32.8 million) with the help of several Big Pharma venture arms.
New investors Johnson & Johnson Innovation – JJDC and RV Invest co-led the Series A, with support from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden. The proceeds will be used to progress Asgard’s lead program, expand its R&D team and support work on new drug modalities and delivery platforms, per a Thursday release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.